LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates. - Dataset (ID:20251)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Mean Relative Cell Count | Standard Error of the Mean for Relative Cell Count | Mean Normalized Growth Rate Inhibition Value | Standard Error of the Mean for Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PF431396 | 1.11 | uM | LJP5 | 0.4063 | 0.0128 | 0.0323 | 0.0408 |
| SK-BR-3 | PF431396 | 3.33 | uM | LJP5 | 0.3797 | 0.0103 | -0.0178 | 0.0410 |
| SK-BR-3 | PF431396 | 10 | uM | LJP5 | 0.3173 | 0.0291 | -0.1410 | 0.1050 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 0.9027 | 0.0647 | 0.8647 | 0.0832 |
| SK-BR-3 | Celastrol | 0.12 | uM | LJP6 | 0.8580 | 0.0418 | 0.7833 | 0.0621 |
| SK-BR-3 | Celastrol | 0.37 | uM | LJP6 | 0.4200 | 0.0173 | 0.0242 | 0.0903 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 0.3239 | 0.0096 | -0.1578 | 0.0679 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 0.2741 | 0.0052 | -0.2584 | 0.0780 |
| SK-BR-3 | Celastrol | 10 | uM | LJP6 | 0.2908 | 0.0177 | -0.2240 | 0.0476 |
| SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 1.0980 | 0.0274 | 1.1438 | 0.0434 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 1.0526 | 0.0333 | 1.0792 | 0.0489 |
| SK-BR-3 | SU11274 | 0.37 | uM | LJP5 | 1.0754 | 0.0225 | 1.1096 | 0.0330 |
| SK-BR-3 | SU11274 | 1.11 | uM | LJP5 | 0.9954 | 0.0248 | 0.9963 | 0.0337 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 0.9462 | 0.0161 | 0.9230 | 0.0186 |
| SK-BR-3 | SU11274 | 10 | uM | LJP5 | 0.3917 | 0.0253 | 0.0063 | 0.0138 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 0.4848 | 0.0171 | 0.1476 | 0.0515 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 0.4177 | 0.0073 | 0.0230 | 0.0664 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 0.3900 | 0.0148 | -0.0304 | 0.0891 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 0.3617 | 0.0133 | -0.0844 | 0.0894 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 0.3408 | 0.0084 | -0.1243 | 0.0802 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 0.2725 | 0.0052 | -0.2613 | 0.0675 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 1.0451 | 0.0410 | 1.0698 | 0.0578 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 1.0028 | 0.0362 | 1.0059 | 0.0515 |
| SK-BR-3 | NVP-AEW541 | 0.37 | uM | LJP5 | 0.9915 | 0.0613 | 0.9927 | 0.0842 |
| SK-BR-3 | NVP-AEW541 | 1.11 | uM | LJP5 | 0.9789 | 0.0378 | 0.9707 | 0.0531 |